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The effect of an exon 12 polymorphism of the human thromboxane synthase
(CYP5A1) gene in stroke patients
Abstract
Background: To examine the prevalence of an exon 12 polymorphism on the human Thromboxane
synthase (CYP5A1) gene.
Material/Methods: Using sequence-specific PCR, we examined the allelic prevalence in 237 Greek
patients with ischemic strokes and in 171 controls. In addition, we compared the CYP5A1 allelic
prevalence in 71 patients with stroke recurrence despite Aspirin use, in comparison with patients who
have not experienced recurrent stroke while taking Aspirin.
Results: The frequencies of the CYP5A1*9mutant (substitution of guanine by adenine near the hemebinding catalytic domain) and of the wild-type allele were 0.197 and 0.803, respectively; they did not differ
significantly between stroke patients and controls. The wildtype allele was more frequent in the Cretan
population compared to continental Greece (OR 1.80, 95% CI 1.19-2.74). The wild-type allele was more
frequent among hypertensive and less frequent among diabetic stroke sufferers, respectively. The
CYP5A1*9 mutant was significantly more prevalent among stroke patients with history of previous
cerebrovascular attacks (p
Conclusions: Allelic prevalence of the CYP5A1 exon 12 might differ between geographic areas within the
same ethnic group, and is associated with particular characteristics of stroke patients. Allele mutations
can abolish the enzymatic activity of thromboxane synthase, via impaired heme binding, associated with
defective response to Aspirin used as secondary prevention, an effect independent from the conventional
risk factors for cerebrovascular disease.
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Summary
Background:
Material/Methods:

To examine the prevalence of an exon 12 polymorphism on the human Thromboxane synthase
(CYP5A1) gene.
Using sequence-speciﬁc PCR, we examined the allelic prevalence in 237 Greek patients with ischemic strokes and in 171 controls. In addition, we compared the CYP5A1 allelic prevalence in 71
patients with stroke recurrence despite Aspirin use, in comparison with patients who have not experienced recurrent stroke while taking Aspirin.

Results:

The frequencies of the CYP5A1*9 mutant (substitution of guanine by adenine near the heme-binding catalytic domain) and of the wild-type allele were 0.197 and 0.803, respectively; they did not differ signiﬁcantly between stroke patients and controls. The wild-type allele was more frequent in the
Cretan population compared to continental Greece (OR 1.80, 95% CI 1.19–2.74). The wild-type allele was more frequent among hypertensive and less frequent among diabetic stroke sufferers, respectively. The CYP5A1*9 mutant was signiﬁcantly more prevalent among stroke patients with history of previous cerebrovascular attacks (p<0.01); and among those who failed secondary Aspirin
prophylaxis even after adjusting for the common risk factors for cardiovascular disease (OR 1.49,
95% CI 1.06–2.11).

Conclusions:

Allelic prevalence of the CYP5A1 exon 12 might differ between geographic areas within the same
ethnic group, and is associated with particular characteristics of stroke patients. Allele mutations
can abolish the enzymatic activity of thromboxane synthase, via impaired heme binding, associated with defective response to Aspirin used as secondary prevention, an effect independent from
the conventional risk factors for cerebrovascular disease.
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BACKGROUND

MATERIAL AND METHODS

Cerebrovascular attacks are leading cause of mortality and
morbidity worldwide [1]. In more than 80% of cases, they
consist of ischemic events within the lumen of cerebral vessels [2], a process in which primary hemostasis and platelets play a cardinal role [3]. Antiplatelet agents, primarily
Aspirin, remain the optimal treatment for primary and secondary prevention of ischemic strokes [4]. The beneﬁcial
action of Aspirin on strokes is affected via inhibition (irreversible acetylation) of the enzyme cyclo-oxygenase, resulting in reduced thromboxane A2 formation. Thromboxane
A2 favors platelet aggregation and vasoconstriction [5]. The
synthetic pathway that leads to thromboxane A2 formation
results in the metabolism of arachidonic acid to prostaglandin and leucotriene derivatives via the sequential activation
of several enzymes [6].

Recruitment of the study population was performed in
two hospitals from different geographic areas of Greece:
“Sotiria” University General Hospital in Athens; and the
“Venizelion” General Hospital, Heraklion, Crete. Two hundred and thirty seven consecutively admitted patients with
a history of documented cerebral ischemic attack, as well
as 171 subjects without a history of cerebrovascular attack
were included in the study. Controls from each centre were
matched to local stroke patients, in terms of age, sex, and
major modiﬁable risk factors for cerebrovascular disease
(smoking, hypertension, diabetes, dyslipidemia). To examine the association between the CYP5A1 SNPs and the protective effect of Aspirin, 71 patients with recurrent stroke
while taking Aspirin were compared with the stroke patients
who did not have any recurrent event while on aspirin secondary prophylaxis.

One of the key enzymes in this process is the thromboxane
synthase (CYP5A1). This is a unique member of family 5
in the cytochrome P450 superfamily and catalyzes the conversion of prostaglandin H2 to thromboxane A2 [7]. A balance between thromboxane A2 and prostacyclin production
is very important for vessel integrity [6]. The mechanism,
however, controlling the formation of these biofactors formed by isomerization of their common precursor prostaglandin H2-remains unknown. Clinically, a deﬁciency of
platelet CYP5A1 activity has been associated with moderate
to severe bleeding disorders [8], but the molecular mechanisms underlying this remain unclear.
The CYP5A1 gene encoding for thromboxane synthase
has been characterised at the long arm of chromosome 7
[9]. It consists of 13 exons and 12 introns, and its size approximates 150Kb. Alternate splicing of the CYP5A1 transcript has been described. The truncated CYP5A1 mRNA
lacks the entire exon 12 encoding the heme-binding domain of the enzyme; the truncated protein is lacking enzymatic activity [10]. In the only relevant study published so
far, genetic polymorphisms of the CYP5A1 gene have been
described in a highly homogeneous French population of
200 healthy volunteers of Caucasian origin: almost 10% of
subjects exhibited at least one out of the 8 missense point
mutations detected [11]. Among the latter, the substitution
of guanine by adenine at the position 1397 of exon 12 signiﬁes the mutant allele designated as CYP5A1*9; the mutation results in Glutamine replacing Arginine as the amino acid 466 of thromboxane synthase [11]. This position is
related to the heme-binding domain that is important for
the catalytic activity of the encoded enzyme [12]. A mutation has also been described in another (1425) position of
exon 12, where substitution of cytosine by thymine leads to
the silent (not causing any change in the encoded protein)
polymorphic allele CYP5A1*1C [11].
Genetic studies have previously suggested the role of CYP
genes in deﬁning genetically susceptible individuals at risk
for tobacco-related cancers, due to impaired hepatic detoxiﬁcation of tobacco substances [13]. In the present casecontrol study we examined the prevalence of the known
CYP5A1 exon 12 genetic polymorphism in stroke patients
with and without Aspirin prophylaxis, as well as in healthy
controls from the island of Crete in comparison with counterparts from continental Greece.

Recruitment study period was 1 year (September 2003–
August 2004). Non-contrast computerized tomography
was performed on all patients within 24 hours of admission, repeated in the following 72 hours or supplemented
by MRI, as appropriate. Additional examinations (i.e. lumbar puncture, septic work-up, etc) were performed as necessary. Patients were excluded from the study if an alternative diagnosis (i.e. hematoma, encephalitis, tumour) was
responsible for the neurologic ﬁndings; if there was radiologic evidence of intracerebral hemorrhage or hemorrhagic transformation; if they had a history of cancer or had received chemotherapy and/or radiotherapy.
Since we focused on the role of CYP5A1 on the Aspirin pathway, patients were also excluded if they had atrial ﬁbrillation
(where the mechanism of stroke is different, and the treatment of choice does not entail Aspirin) or when the stroke
was classiﬁed of cardioembolic origin, as well as if they were
on oral anticoagulants or antiplatelet therapy other than
Aspirin (i.e. dipyridamole, clopidogrel). Stroke patients
were classiﬁed according to the TOAST diagnostic system
[14]. Risk factors for cerebrovascular disease were assessed
according to standard deﬁnitions [15]. Dyslipidemia was deﬁned by pharmacological treatment, total serum cholesterol >6.2 mmol/L or LDL-cholesterol >4.1 mmol/L.
During the 12 months of the recruitment period, 511 patients were considered for inclusion in the study. Out of
those, intracerebral hemorrhage was diagnosed in 58; for
another 70 patients an alternative intracerebral pathology (i.e. hematoma, tumour, infection) accounted for the
neurologic ﬁndings. A further 146 patients were excluded because of other reasons (cardioembolic stroke, atrial
ﬁbrillation and/or anticoagulation, use of other antiplatelet treatment, refusal to provide sample, etc). Main characteristics of patients and controls included in the study are
shown in Table 1.
Peripheral blood from study subjects was collected in EDTA
anticoagulated tubes. Genomic DNA was extracted from
whole blood using proteinase K, followed by phenol extraction and ethanol precipitation according to standard
procedures [16]. DNA was resuspended in 50 μl TE buffer
(10 mM Tris-HCl, 1 mM EDTA, pH 8.0). DNA purity was
assessed by a UV/VIS spectrophotometer evaluating the
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Table 1. Main characteristics of the study population.
Patients N=237Controls N=171
Mean age (Range)

A260/A280 ratio. Working stocks were prepared by 10-fold dilution in double distilled H2O.
p

77.3 (47–99)

76.8 (43–96)

NS

Male (%)

114 (48.2)

83 (48.5)

NS

Female (%)

123 (51.8)

88 (51.5)

Continental Greece (%)

173 (73)

125 (73.1)

Crete (%)

64 (27)

46 (26.9)

12 (5.1)

10 (5.8)

Sex

Origin
NS

Risk factors1
None (%)

NS

One (%)

50 (21.1)

39 (22.8)

More than one (%)

175 (73.8)

122 (71.4)

Smokers (%)

73 (30.8)

53 (30.9)

Hypertension (%)

193 (81.4)

133 (77.8)

NS

Diabetes (%)

92 (38.8)

56 (32.7)

NS

Dyslipidemia2 (%)

83 (35)

62 (36.2)

NS

Total chol. mmol/L
(mean ±SD)

6.6 (3.8)

6.4 (3.9)

LDL-chol. mmol/L (mean
±SD)

4.4 (3)

4.1 (3.1)

HDL-chol. mmol/L (mean
±SD)

1.1 (0.6)

1 (0.5)

No evidence (%)

108 (45.6)

NA

One (%)

77 (32.5)

NA

52 (21.9)

NA

TIA

28 (11.8)

NA

LVD

94 (39.7)

NA

SVD

82 (34.6)

NA

IU

33 (13.9)

NA

NS

3

Previous CVA

More than one (%)
4

Classification

Daily Aspirin dose

NA

No

166 (70)

100 mg/day

15 (6.3)

NA

160 mg/day

27 (11.4)

NA

325 mg/day

29 (12.3)

NA

1

Denotes the major modifiable risk factors for cerebrovascular disease:
smoking, hypertension, diabetes mellitus, dyslipidemia.
2
Presence of one of the following: pharmacological treatment, total
serum cholesterol >6.2 mmol/L, LDL-cholesterol >4.1 mmol/L.
3
Includes ischemic strokes and/or documented transient ischemic
attacks (TIA). CVA – cerebrovascular attack; NA – not applicable; NS
– not statistically significant.
4
According to the TOAST diagnostic system (see Ref. 14 for details):
LVD – large-vessel disease; SVD – small-vessel disease; IU – ischemic
stroke of undetermined etiology. Patients with cardioembolic
disease, hemorrhage or acute stroke of etiology other (than ischemic)
have been excluded from this study.
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An allele-speciﬁc polymerase chain reaction (AS-PCR) approach [17] was used to detect the presence of polymorphisms at the 1397 site of exon 12. We designed sequence
speciﬁc primers with mismatches at the 3’ end to identify
each variant, which, in combination with a consensus primer, resulted in a PCR product of expected size if the speciﬁc
allelic variant was present. A set of appropriate control primers conﬁrmed PCR ampliﬁcation in the reactions where speciﬁc allele ampliﬁcation was absent: the presence of an allele-speciﬁc band of the expected size in conjunction with
a control band was considered to be positive evidence for
each particular allele. The absence of an allele-speciﬁc band
with presence of a control band was considered to be negative indication for a particular allele. The allele-speciﬁc and
control primers we used are shown in Table 2.
PCR assays were performed by introducing 100 ng of genomic DNA in a PCR reaction mixture containing 1X PCR
buffer, 250 μM dNTPs, 2.0 mM MgCl2, 0.2 mM each allelespeciﬁc primer, 0.1 mM each control primer, and 0.2 U Taq
DNA polymerase (Life Technologies Ltd., UK) to a 25 μl
total reaction volume. The cycling parameters were as follows: 2 minutes at 95°C, 34 cycles of 30 seconds at 94°C, 50
seconds at 60°C, and 25 seconds at 72°C, 21 cycles of 25 seconds at 96°C, 50 seconds at 65°C, and 5 minutes at 72°C.
The PCR products were visualized by agarose gel (2%) electrophoresis after ethidium bromide staining.
To conﬁrm results produced by AS-PCR, randomly selected samples (1 out of 10) from all variants (homozygous for
each genotype and heterozygous) were analyzed by dye primer cycle sequencing on an ABI 377 automated sequencer
(PE Applied Biosystems, Warrington, UK), using the same
allele-speciﬁc and consensus primer.
Data were analyzed using SPSS for Windows, release 12.0.1
(SPSS, Chicago, IL, USA). To determine whether the distribution of the exon 12 CYP5A1 genotypes fulﬁlled the HardyWeinberg equilibrium, the c2 test was used to compare the
observed number of subjects with the expected number. In
addition, continuous variables (i.e. age) were examined using
one-way analysis of variance. Variables distributed in a nonparametric fashion were examined using the Mann-Whitney
U or the Kruskal-Wallis test, as appropriate. Normality was
tested using the Kolmogorov-Smirnov test.
Our sample could provide us 90% power (with a 0.05) to detect at least 10% difference in the prevalence of the rare allele between stroke patients and controls, supposing the latter
15%. For the same power and statistical signiﬁcance level, a
sample of 133 patients would sufﬁce for the detection of stroke
recurrence on aspirin, should the mutant allele be overrepresented at an excess rate of 20% among stroke re-sufferers,
in comparison to our reference stroke population.
In the stroke cohort, a logistic regression model was constructed to examine the relationship between CYP5A1 allelotypes and stroke recurrence on Aspirin prophylaxis, using
the following covariates: age, gender, stroke type, smoking
status, diabetes mellitus, hypertension, dyslipidemia, use of
statin and aspirin dose.
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Table 2. Primers for polymerase chain reaction amplification of CYP5A1 exon 12 polymorphic sites.
Gene
CYP5A1 ex.12

Polymorphism Annealing position
+1397 G/A*

Primer sequence

Product size

1375-1397

F- gctgaggcccggcagcagcaccg/A

120 bp

1495-1471

R- gcagcacgtggagcagtgtcaactt

GAPDH

F- GGAAGGTGAAGGTCGGAGTCA

101 bp

R- GTCATTGATGGCAACAATATCCACT
* Position referred to the ATG translation start site as +1.
among Cretan subjects, compared with those originated from
continental Greece (Odds Ratio for the wild-type 1.80, 95%
Conﬁdence Intervals 1.19–2.74; p=0.005). This difference was
observed even when stroke patients were analyzed separately
(OR 1.81, 95% CI 1.04–3.14; p=0.036) (Table 3). Given this
difference in allelic prevalence between mainland Greek and
Cretan populations, the Odds Ratios for all following analysis
in stroke patients were corrected for place of origin.

Figure 1. Genotype analysis of CYP5A1 exon 12. Electrophoresis
patterns for wild-type allele (top) and mutant
allele (bottom). From left to right: Lanes 1, 2 and 4
– heterozygous cases; Lane 5 – CYP5A1 wild-type
homozygosity; Lane 6 – CYP5A1*9 homozygosity; Lane
7 – 100bp DNA ladder.
Approval to conduct this research was obtained from Ethics’
Committees in both participating hospitals.

RESULTS
Representative examples of homozygous for the wild-type,
CYP5A1*9 homozygous and heterozygous cases are shown
in Figure 1. The allelic frequencies of the wild-type CYP5A1
exon 12 and of the CYP5A1*9 mutant among the study population were 0.803 and 0.197, respectively; these did not differ
signiﬁcantly between stroke patients and controls (Table 3).
There was under-representation of the CYP5A1*9 allele

Among stroke patients, the presence of the CYP5A1 wildtype allele was more frequent among the hypertensives (OR
1.68, 95% CI 1.01–2.79; p=0.045), and less frequent among
the diabetics (OR 0.55, 95% CI 0.36–0.84; p=0.006) (Table
3). Also among stroke patients, the CYP5A1*9 mutant was
signiﬁcantly more prevalent among those who suffered a recurrent stroke while receiving Aspirin, compared to those
with successful secondary Aspirin prophylaxis (OR 1.73,
95% CI 1.10–2.73; p=0.017). After adjusting for aspirin dose,
use of statins and conventional risk factors for cardiovascular disease (age, gender, smoking status, diabetes mellitus,
hypertension, dyslipidemia) the overrepresentation of the
CYP5A1*9 mutant among stroke resufferers remained statistically signiﬁcant (OR 1.49, 95% CI 1.06–2.11; p=0.038)
(Table 3). The adjusted allelic frequencies of the CYP5A1*9
mutant among ﬁrst-ever stroke sufferers, patients with one
previous stroke, and those with history of multiple cerebrovascular attacks were 0.199, 0.272, and 0.280, respectively;
p<0.01 (Table 3). Regarding stroke types, the CYP5A1*9 mutant was more prevalent among patients with small-vessel disease and (less so) among those with TIA compared with patients with large-vessel disease, but this difference was not
statistically signiﬁcant in multivariate analysis (Table 3).
There was no association between the genotype distribution
of exon 12 alleles and age, sex and the presence of risk factors for cardiovascular disease other than those in Table 3
(i.e. family history, obesity, value of high-sensitivity C-reactive protein, etc) (data not shown).

DISCUSSION
In this case-control study, we examined the allelic frequencies
of a SNP on exon 12 of the thromboxane synthase (CYP5A1)
gene in Greek stroke patients and controls. The allelic frequency of the mutant CYP5A1*9 (that contains adenine instead of guanine at the position 1397) was 0.197 among
our study population; this was higher than the frequency of
CYP5A1*9 (3.75%) found among another Caucasian (French)
population in the only relevant study existing thus far [11].
Interestingly, the frequency of CYP5A1*9 was signiﬁcantly
lower among the study subjects originating form the island
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Table 3. Allelic frequencies of the CYP5A1 exon 12 among the study population.
N
All

All subjects (408)
1

CYP5A1 wt

2

CYP5A1*9

408

0.803

0.197

Patients

237

0.812

0.188

Controls

171

0.792

0.208

Crete

110

0.855

0.145

Continental
Greece

298

0.765

0.235

Yes

126

0.762

0.238

No

282

0.761

0.239

Yes

326

0.773

0.227

No

82

0.707

0.293

Yes

148

0.740

0.260

No

260

0.769

0.231

Yes

145

0.755

0.245

No

263

0.764

0.236

OR (95% CI)

N

Stroke patients (237)
CYP5A1 wt

CYP5A1*9

OR (95% CI)

64

0.859

0.141

1.81 (1.04–3.14)

173

0.772

0.228

73

0.822

0.178

164

0.750

0.250

193

0.782

0.218

44

0.682

0.318

Status
NS

Origin
1.80 (1.19–2.74)

Smoking
NS

NS

Hypertension
NS

1.68 (1.01–2.79)

Diabetes
NS

92

0.701

0.299

145

0.810

0.190

83

0.732

0.268

154

0.789

0.211

Yes

71

0.711

0.289

No

166

0.810

0.190

0.55 (0.36–0.84)

Dyslipidemia
NS

NS

Aspirin use3

Previous CVA3,4

p<0.016

No evidence

108

0.801

0.199

One

77

0.728

0.272

Multiple

52

0.720

0.280

Classification5

NS6

TIA

28

0.714

0.286

LVD

94

0.782

0.218

SVD

82

0.690

0.310

IU

33

0.818

1

2

1.49 (1.06–2.11)6

3

0.182
4

Wild-type; Allele that contains adenine instead of guanine at position +1397; Among stroke patients only; CVA – cerebrovascular attack; those
include ischemic strokes and/or documented transient ischemic attacks (TIA); 5 LVD – large-vessel disease; SVD – small-vessel disease; IU – ischemic
stroke of undetermined etiology; 6 Adjusted for age, sex, diabetes, hypertension, smoking, dyslipidemia, aspirin dose and statin use.
NS – not statistically significant, OR – Odds Ratio (analysis for stroke patients was corrected for place of origin).

of Crete, compared with the continental Greek population;
this difference was also observed when stroke patients were
analysed separately. Different mutation frequencies among
ethnic groups and subpopulations have been described for
other polymorphic cytochromes P450 [18,19].
Prevalence of CYP5A1 allelic forms in our study did not
signiﬁcantly differ between patients and controls. We

BR34

note, however, that stroke sufferers despite Aspirin prophylaxis were more likely to be carriers of the CYP5A1*9
mutant than homozygous for the wild-type allele, even
after adjusting for the common risk factors for cardiovascular disease. Similarly, the CYP5A1*9 mutant prevailed among stroke patients with history of a previous
cerebrovascular attack, compared to ﬁrst-ever stroke sufferers (p<0.01).

Med Sci Monit, 2009; 15(1): BR30-35

Interestingly, correlations between the CYP5A1*9 allele and
both hypertension and diabetes (two of the major risk factors
for stroke) were also recorded in our population. The significance of these relationships remains to be clariﬁed; the fact,
however, that overrepresentation of the mutant allele in patients resuffering from stoke while taking Aspirin remained
after adjusting for the major risk factors for cardiovascular
disease might imply for an independent role for this allele
on the efﬁcacy of the arachidonic acid metabolism pathway.
Interestingly also, all correlations in stroke patients remained
signiﬁcant even after correction for place of origin, and this
may signify for an effect of CYP5A1 on stroke pathophysiology, additional to that conferred by ethnic predisposition.
Distribution of the mutated alleles did not differ among
the different ischemic stroke subtypes in our study. This
is particularly interesting for the case of the lacunar infarcts, whose pathophysiology is thought to differ from the
rest ischemic strokes, and perhaps underlines the cardinal
role of platelet-mediated thrombosis in the pathogenesis
of brain infarcts [20].
A limitation to the interpretation of these results is that the
metabolic activity of the genetic variants of thromboxane
synthase has not been studied in depth as yet. Interestingly
however, the CYP5A1*9 allele denotes a substitution near
the heme-binding area of the protein [11]. Mutations in
this area can abolish the enzymatic activity of thromboxane
synthase, via impaired heme binding [12]. The increased
frequency of the mutant CYP5A1*9 allele, interpreted in
this context, may signify a population at risk for repeated
ischemic strokes despite Aspirin prophylaxis, due to defective function of thromboxane synthase. The ﬁndings at the
gene level presented herein may herald the functional studies required to dismiss or validate the hypothesis above. In
this context, the frequency and signiﬁcance of the alternative splicing that results in lack of the entire exon 12 need
further investigation [21]. The effect of polymorphisms in
other areas of the gene similarly merits further investigation. Finally, the validity of our results in other populations
and ethnic groups remain to be determined.

Kimouli M et al – Thromboxane synthase gene polymorhisms in stroke

recurrent cerebrovascular attacks in patients who fail secondary prophylaxis with Aspirin. Additional genetic and functional studies of the other polymorphic variants described
on the CYP5A1 gene are expected to clarify the role of the
thromboxane synthase enzyme in cerebrovascular disease.
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